CommercialBilling CodesMedium impact
11.07.01ab, Hematopoietic Stem Cell Transplantation (Bone Marrow Transplant)
Independence Blue Cross·Hematology, Oncology, Transplant Surgery +1 more·Medical Policy
Effective date
Jul 1, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross updated policy 11.07.01ab to 11.07.01ad, adding HCPCS code C9173 (filgrastim-txid/nypozi biosimilar) effective 07/01/2025. This biosimilar injection code is now recognized as a covered associated procedure for hematopoietic stem cell transplantation mobilization. Billing teams must update systems to recognize this new code for proper claim submission and reimbursement.
Action Required
By July 1, 2025: Billing team must update billing software and claim submission systems to recognize and process HCPCS code C9173 (filgrastim-txid biosimilar) as a covered code for hematopoietic stem cell transplantation procedures under policy 11.07.01ad. Verify that billing system accepts C9173 alongside existing mobilization codes (J1442, Q5101, J1447). Update internal billing guidelines and provider training materials to reflect the new biosimilar option. Ensure claims submitted on or after 07/01/2025 include the correct code for filgrastim-txid administration. Reject or correct any claims submitted with outdated policy version 11.07.01ab after the effective date.